Papillary thyroid carcinoma susceptibility candidate 3 (non-protein coding) (PTCSC3)

PTCSC3 is a long intergenic non-coding RNA with highly thyroid-specific expression that acts as a tumor suppressor by negatively regulating cellular proliferation, promoting cell cycle arrest and apoptosis, and inhibiting cancer cell motility, invasion, and metastasis[1][4][5]. It regulates genes involved in DNA replication, repair, and cancer-related pathways such as Wnt, STAT3, and Hippo signaling[2]. Genetic polymorphisms (such as rs944289) that reduce PTCSC3 expression are linked to increased risk of papillary thyroid carcinoma[1][3]. PTCSC3 also interacts with specific microRNAs (like miR-574-5p and MIR100HG) to influence cancer phenotypes in thyroid, breast, gastric, and other cancers[2][4][5][6]. It is downregulated in tumor tissues, and its restoration can suppress cell growth and promote apoptosis, highlighting its potential utility as a biomarker for cancer susceptibility, progression, and prognosis[1][2][3][4][5]. There are no approved drugs directly targeting PTCSC3; clinical utility might require development of RNA-based therapeutics or gene restoration methods.

Other names

PTCSC3Papillary thyroid carcinoma susceptibility candidate 3 (non-protein coding)Long non-coding RNA PTCSC3lncRNA PTCSC3

Drugs targeting lncRNAs are investigational; known mechanisms involve restoring PTCSC3 expression to promote tumor suppressor activity, alter cell proliferation, induce apoptosis, and suppress invasion/metastasis through the effects on downstream targets (such as S100A4, MIR100HG, etc.)